Although it is far too early to describe serum NGAL as reliable biomarker for vulnerable CAS in patients with T2DM, enhanced NGAL concentrations in the circulation did not meet statistical significance for patients with a history of peripheral artery disease or CAD as described by Giaginis et al. previously [38]. Here, LCN2 is linked to peripheral arterial disease.